Mylan launches first generic Doryx Delayed-Release Tablets, 200 mg

Doxycycline Hyclate DR Tablets are a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne.

Doxycycline Hyclate DR Tablets USP, 200 mg, had US sales of approximately $181.8 million for the 12 months ending 31 March 2016, according to IMS Health.

Currently, Mylan has 258 ANDAs pending FDA approval representing $109 billion in annual brand sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $37.4 billion in annual brand sales, for the 12 months ending 31 December 2015, according to IMS Health.